Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...
Medpage Today on MSN5mon
Cytokine Release Syndrome and Neurotoxicity After CAR T-Cell TherapyTocilizumab -- an interleukin (IL)-6 receptor inhibitor -- was approved by the FDA in 2017 for the treatment of severe or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback